Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans

Bernard Coulie, Lawrence Szarka, Michael Camilleri, Duane D. Burton, Sanna McKinzie, Nancy Stambler, Jesse M. Cedarbaum

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Background and Aims: The aim of this study was to assess the effects of recombinant human brain-derived neurotrophic factor (r-metHuBDNF) and recombinant human neurotrophic factor 3 (r-metHuNT-3) on gastrointestinal motor functions in healthy people and in patients with constipation. Methods: Gastrointestinal and colonic transit was measured by scintigraphy before and after 2 weeks of treatment. Daily diaries documented symptoms over 6 weeks before, during, and after treatment. In a randomized study of healthy subjects, 40 received 100 μ/kg r-metHuBDNF or placebo subcutaneously (SC) daily. In a separate study, 8 healthy subjects and 8 patients with constipation received 300 μ/kg r-metHuNT-3 SC thrice weekly. Results: r-met- HuBDNF accelerated overall and proximal colonic emptying (P <0.05) in health, r-metHuNT-3 accelerated overall colonic transit in health and constipation (all P <0.05) and gastric and small bowel transit (both P <0.05) in health, r-metHuBDNF tended to increase stool frequency compared with placebo in health (P = 0.09). r-metHuNT-3 increased stool frequency (P = 0.05) and facilitated passage of stool (P <0.01) in constipated patients. The effects on stool frequency started within 3 days of the beginning of neurotrophin administrations and lasted up to 5 days after treatment ended, r-metHu neurotrophic factors were well tolerated, although half of the participants in the 2 studies developed injection site reactions or paresthesiae. Conclusions: Exogenous neurotrophic factors stimulate human gut motility in health and constipation.

Original languageEnglish (US)
Pages (from-to)41-50
Number of pages10
JournalGastroenterology
Volume119
Issue number1
StatePublished - Jul 2000

Fingerprint

Nerve Growth Factors
Constipation
Health
Healthy Volunteers
Placebos
Gastrointestinal Transit
Paresthesia
Radionuclide Imaging
Stomach
Therapeutics
Injections

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Coulie, B., Szarka, L., Camilleri, M., Burton, D. D., McKinzie, S., Stambler, N., & Cedarbaum, J. M. (2000). Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology, 119(1), 41-50.

Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. / Coulie, Bernard; Szarka, Lawrence; Camilleri, Michael; Burton, Duane D.; McKinzie, Sanna; Stambler, Nancy; Cedarbaum, Jesse M.

In: Gastroenterology, Vol. 119, No. 1, 07.2000, p. 41-50.

Research output: Contribution to journalArticle

Coulie, B, Szarka, L, Camilleri, M, Burton, DD, McKinzie, S, Stambler, N & Cedarbaum, JM 2000, 'Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans', Gastroenterology, vol. 119, no. 1, pp. 41-50.
Coulie, Bernard ; Szarka, Lawrence ; Camilleri, Michael ; Burton, Duane D. ; McKinzie, Sanna ; Stambler, Nancy ; Cedarbaum, Jesse M. / Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. In: Gastroenterology. 2000 ; Vol. 119, No. 1. pp. 41-50.
@article{093d9ae5c8de44a5b398375728153c42,
title = "Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans",
abstract = "Background and Aims: The aim of this study was to assess the effects of recombinant human brain-derived neurotrophic factor (r-metHuBDNF) and recombinant human neurotrophic factor 3 (r-metHuNT-3) on gastrointestinal motor functions in healthy people and in patients with constipation. Methods: Gastrointestinal and colonic transit was measured by scintigraphy before and after 2 weeks of treatment. Daily diaries documented symptoms over 6 weeks before, during, and after treatment. In a randomized study of healthy subjects, 40 received 100 μ/kg r-metHuBDNF or placebo subcutaneously (SC) daily. In a separate study, 8 healthy subjects and 8 patients with constipation received 300 μ/kg r-metHuNT-3 SC thrice weekly. Results: r-met- HuBDNF accelerated overall and proximal colonic emptying (P <0.05) in health, r-metHuNT-3 accelerated overall colonic transit in health and constipation (all P <0.05) and gastric and small bowel transit (both P <0.05) in health, r-metHuBDNF tended to increase stool frequency compared with placebo in health (P = 0.09). r-metHuNT-3 increased stool frequency (P = 0.05) and facilitated passage of stool (P <0.01) in constipated patients. The effects on stool frequency started within 3 days of the beginning of neurotrophin administrations and lasted up to 5 days after treatment ended, r-metHu neurotrophic factors were well tolerated, although half of the participants in the 2 studies developed injection site reactions or paresthesiae. Conclusions: Exogenous neurotrophic factors stimulate human gut motility in health and constipation.",
author = "Bernard Coulie and Lawrence Szarka and Michael Camilleri and Burton, {Duane D.} and Sanna McKinzie and Nancy Stambler and Cedarbaum, {Jesse M.}",
year = "2000",
month = "7",
language = "English (US)",
volume = "119",
pages = "41--50",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans

AU - Coulie, Bernard

AU - Szarka, Lawrence

AU - Camilleri, Michael

AU - Burton, Duane D.

AU - McKinzie, Sanna

AU - Stambler, Nancy

AU - Cedarbaum, Jesse M.

PY - 2000/7

Y1 - 2000/7

N2 - Background and Aims: The aim of this study was to assess the effects of recombinant human brain-derived neurotrophic factor (r-metHuBDNF) and recombinant human neurotrophic factor 3 (r-metHuNT-3) on gastrointestinal motor functions in healthy people and in patients with constipation. Methods: Gastrointestinal and colonic transit was measured by scintigraphy before and after 2 weeks of treatment. Daily diaries documented symptoms over 6 weeks before, during, and after treatment. In a randomized study of healthy subjects, 40 received 100 μ/kg r-metHuBDNF or placebo subcutaneously (SC) daily. In a separate study, 8 healthy subjects and 8 patients with constipation received 300 μ/kg r-metHuNT-3 SC thrice weekly. Results: r-met- HuBDNF accelerated overall and proximal colonic emptying (P <0.05) in health, r-metHuNT-3 accelerated overall colonic transit in health and constipation (all P <0.05) and gastric and small bowel transit (both P <0.05) in health, r-metHuBDNF tended to increase stool frequency compared with placebo in health (P = 0.09). r-metHuNT-3 increased stool frequency (P = 0.05) and facilitated passage of stool (P <0.01) in constipated patients. The effects on stool frequency started within 3 days of the beginning of neurotrophin administrations and lasted up to 5 days after treatment ended, r-metHu neurotrophic factors were well tolerated, although half of the participants in the 2 studies developed injection site reactions or paresthesiae. Conclusions: Exogenous neurotrophic factors stimulate human gut motility in health and constipation.

AB - Background and Aims: The aim of this study was to assess the effects of recombinant human brain-derived neurotrophic factor (r-metHuBDNF) and recombinant human neurotrophic factor 3 (r-metHuNT-3) on gastrointestinal motor functions in healthy people and in patients with constipation. Methods: Gastrointestinal and colonic transit was measured by scintigraphy before and after 2 weeks of treatment. Daily diaries documented symptoms over 6 weeks before, during, and after treatment. In a randomized study of healthy subjects, 40 received 100 μ/kg r-metHuBDNF or placebo subcutaneously (SC) daily. In a separate study, 8 healthy subjects and 8 patients with constipation received 300 μ/kg r-metHuNT-3 SC thrice weekly. Results: r-met- HuBDNF accelerated overall and proximal colonic emptying (P <0.05) in health, r-metHuNT-3 accelerated overall colonic transit in health and constipation (all P <0.05) and gastric and small bowel transit (both P <0.05) in health, r-metHuBDNF tended to increase stool frequency compared with placebo in health (P = 0.09). r-metHuNT-3 increased stool frequency (P = 0.05) and facilitated passage of stool (P <0.01) in constipated patients. The effects on stool frequency started within 3 days of the beginning of neurotrophin administrations and lasted up to 5 days after treatment ended, r-metHu neurotrophic factors were well tolerated, although half of the participants in the 2 studies developed injection site reactions or paresthesiae. Conclusions: Exogenous neurotrophic factors stimulate human gut motility in health and constipation.

UR - http://www.scopus.com/inward/record.url?scp=0034234832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034234832&partnerID=8YFLogxK

M3 - Article

C2 - 10889153

AN - SCOPUS:0034234832

VL - 119

SP - 41

EP - 50

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -